Pharma companies, universities, and others worry that drug and biomedical discoveries will be thwarted by the cost of access to patented research tools such as databases, peptides, biomarkers, and bioassays.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva